

S 775

Increasing Transparency in Generic Drug Applications Act

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Mar 14, 2023

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Mar 14, 2023)

Official Text: https://www.congress.gov/bill/118th-congress/senate-bill/775

Sponsor

Name: Sen. Hassan, Margaret Wood [D-NH]

Party: Democratic • State: NH • Chamber: Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Paul, Rand [R-KY]	R · KY		Mar 14, 2023
Sen. Braun, Mike [R-IN]	R · IN		Mar 28, 2023
Sen. Hickenlooper, John W. [D-CO]	D · CO		Apr 25, 2023

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Mar 14, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 3561	Related bill	Dec 17, 2024: Referred to the Subcommittee on Health.
118 HR 5378	Related bill	Dec 11, 2023: Motion to reconsider laid on the table Agreed to without objection.
118 S 1114	Related bill	Jun 22, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 108.
118 HR 3839	Related bill	Jun 9, 2023: Referred to the Subcommittee on Health.

Summary (as of Mar 14, 2023)

Increasing Transparency in Generic Drug Applications Act

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

Actions Timeline

- **Mar 14, 2023:** Introduced in Senate
- **Mar 14, 2023:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.